Subjective Well Being of Schizophrenic Patients in Greece
AURA
1 other identifier
observational
600
1 country
24
Brief Summary
Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication. Moreover it aims to assess their adherence to the treatment and will investigate whether there is any correlation of these factors with the clinical condition of these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2009
Shorter than P25 for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2009
CompletedFirst Submitted
Initial submission to the registry
March 3, 2009
CompletedFirst Posted
Study publicly available on registry
March 6, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2009
CompletedDecember 9, 2010
December 1, 2010
7 months
March 3, 2009
December 7, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Assessment of Subjective well being
Relative score reported in SWBN scale at the visit. No baseline comparison
Assessment of functioning
Relative score reported in GAF scale at the visit. No baseline comparison
Secondary Outcomes (3)
Assessment of Compliance to therapy
Relative score reported in BARS scale at the visit. No baseline comparison
Assessment of General Psychopathology
Relative score reported in PANNS scale at the visit. No baseline comparison
Assessment of Clinical Condition
Relative score reported in CGIS scale at the visit. No baseline comparison
Eligibility Criteria
Target Group:Patients suffering from Schizophrenia treated in private practice
You may qualify if:
- Provision of written informed consent
- Diagnosis of schizophrenia according to DSM-IV
- The patient must have been prescribed an atypical antipsychotic for at least 4 weeks before the first study visit
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (24)
Research Site
Agrinio, Greece
Research Site
Alexsandroupoli, Greece
Research Site
Argos, Greece
Research Site
Arta, Greece
Research Site
Athens, Greece
Research Site
Crete, Greece
Research Site
Drama, Greece
Research Site
Edessa, Greece
Research Site
Elefsina, Greece
Research Site
Giannitsá, Greece
Research Site
Ioannina, Greece
Research Site
Karditsa, Greece
Research Site
Katerini, Greece
Research Site
Kavala, Greece
Research Site
Kozani, Greece
Research Site
Larissa, Greece
Research Site
Pátrai, Greece
Research Site
Piraeus, Greece
Research Site
Preveza, Greece
Research Site
Rhodes, Greece
Research Site
Serres, Greece
Research Site
Thebes, Greece
Research Site
Thessaloniki, Greece
Research Site
Volos, Greece
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Errikos Tzempelikos, Dr
Sismanoglio Hospital, Psychiatric Department, Greece
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 3, 2009
First Posted
March 6, 2009
Study Start
March 1, 2009
Primary Completion
October 1, 2009
Study Completion
October 1, 2009
Last Updated
December 9, 2010
Record last verified: 2010-12